Sunitinib
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Oncology & Critical Care treatment.
🧴 Clinical Application
RCC and GIST: Take orally 50 mg once daily for 4 consecutive weeks, followed by a 2-week rest period (4/2 schedule) with or without food. pNET: Take 37.5 mg once daily continuously. Swallow capsules whole.
⚠️ Side Effects
Common: Fatigue/asthenia, diarrhea, hypertension, nausea, hand-foot syndrome, stomatitis, yellowish skin discoloration and hair depigmentation, hypothyroidism. Rare/Severe: Severe hepatotoxicity / liver failure, left ventricular dysfunction / congestive heart failure, osteonecrosis of the jaw (ONJ), and thrombotic microangiopathy.
🛡️ Safety Warnings
Black Box Warning: Severe, potentially fatal hepatotoxicity; monitor liver enzymes at baseline, during each cycle, and as clinically indicated. Monitor blood pressure, thyroid function (TSH), and left ventricular ejection fraction regularly. Routine dental exam recommended prior to therapy to reduce osteonecrosis of the jaw risk.
Jan Aushadhi Products containing Sunitinib
Found 2 generic formulation(s) containing this active ingredient.
Sunitinib Capsules 12.5mg
Sunitinib Capsules (12.5mg, 25mg) is an oral multi-targeted receptor tyrosine kinase inhibitor on the WHO Model List of Essential Medicines. It blocks signaling by VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-alpha, PDGFR-beta, c-KIT, FLT3, and RET, exerting powerful anti-angiogenic and direct antiproliferative effects. Indicated for advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib, and progressive neuroendocrine tumors of pancreatic origin (pNET).
Sunitinib Capsules 25mg
Sunitinib Capsules (12.5mg, 25mg) is an oral multi-targeted receptor tyrosine kinase inhibitor on the WHO Model List of Essential Medicines. It blocks signaling by VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-alpha, PDGFR-beta, c-KIT, FLT3, and RET, exerting powerful anti-angiogenic and direct antiproliferative effects. Indicated for advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib, and progressive neuroendocrine tumors of pancreatic origin (pNET).
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Sunitinib.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Sunitinib Capsules 12.5mg | 28's Bottle | ₹499.00 | SUTINAT, RCNET | ₹5370.97 | 91% Save |
| Sunitinib Capsules 25mg | 28's Bottle | ₹910.00 | SUTIB, RCNET, SUNISAM, SUTENT, SUTINAT | ₹26328.46 | 97% Save |
Frequently Asked Questions (FAQ)
Get answers to common queries about Sunitinib generics.